RMTI Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Company profile

Russell Ellison
Fiscal year end
Former names
IRS number
SEC advisor number
FINRA CRD number
$234.04M (as of 4 Sep 20)
2,081 (as of 4 Sep 20)
13 (3 investment advisory or research)
Rockwell Medical
MI 48393
Office hours
Monday - Friday, MO - THU: 8 A.M. - 6 P.M. & FRI : 8 A.M. - 12 P.M.
Owner Title From %Ownership
Richmond, David, Scott President 09/2011 50-75%
Curfman, Matthew, Jeremy Senior Vice President of Investment Services 09/2011 10-25%
Pirner, Gary, Matthew Chief Compliance Officer 12/2018 < 5%

RMTI stock data


Investment data

Data from SEC filings
Securities sold
Number of investors
Regulatory AUM / Assets Under Management
Number of accounts
Number of employees


31 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 48.68M 48.68M 48.68M 48.68M 48.68M 48.68M
Cash burn (monthly) 2.64M (positive/no burn) 2.69M 2.37M 2.86M 2.47M
Cash used (since last report) 9.1M n/a 9.26M 8.15M 9.83M 8.5M
Cash remaining 39.58M n/a 39.42M 40.53M 38.85M 40.18M
Runway (months of cash) 15.0 n/a 14.7 17.1 13.6 16.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Dec 20 Richmond David S. Sell Dispose S Yes No 1.03 42,450 43.72K 1,433,309
11 Dec 20 Allen Nissenson Common Stock Grant Aquire A No No 0 1,488 0 24,488
11 Dec 20 Andrea Heslin Smiley Common Stock Grant Aquire A No No 1.12 18,601 20.83K 18,601
11 Dec 20 Andrea Heslin Smiley Call Option Call Option (right to buy) Grant Aquire A No No 1.12 26,042 29.17K 26,042
7 Dec 20 Ravich Mark H Common Stock Other Aquire J Yes No 1.224 219,905 269.16K 219,905
7 Dec 20 Ravich Mark H Common Stock Other Dispose J Yes No 1.224 219,905 269.16K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

28.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 91 88 +3.4%
Opened positions 14 24 -41.7%
Closed positions 11 13 -15.4%
Increased positions 34 19 +78.9%
Reduced positions 19 26 -26.9%
13F shares
Current Prev Q Change
Total value 80.04M 164.09M -51.2%
Total shares 26.44M 25M +5.7%
Total puts 0 60K EXIT
Total calls 50.4K 58.1K -13.3%
Total put/call ratio 1.0
Largest owners
Shares Value Change
CVI Investments 4.91M $4.96M NEW
BLK Blackrock 4.79M $4.84M +5.9%
Vanguard 2.79M $2.82M +6.0%
Perkins Capital Management 2.46M $2.48M +33.2%
STT State Street 1.2M $1.21M +44.8%
CVI 1.11M $1.12M -79.1%
Renaissance Technologies 970.61K $980K +250.6%
Geode Capital Management 888.97K $897K -4.3%
NTRS Northern Trust 858.56K $867K +1.6%
MS Morgan Stanley 769.64K $777K +871.6%
Largest transactions
Shares Bought/sold Change
CVI Investments 4.91M +4.91M NEW
CVI 1.11M -4.2M -79.1%
Sabby Management 611.99K -2.98M -83.0%
Renaissance Technologies 970.61K +693.8K +250.6%
MS Morgan Stanley 769.64K +690.43K +871.6%
Perkins Capital Management 2.46M +613.2K +33.2%
Aqr Capital Management 423K +423K NEW
STT State Street 1.2M +371.92K +44.8%
BLK Blackrock 4.79M +267.8K +5.9%
Citadel Advisors 201.86K +158.94K +370.2%

Financial report summary

  • If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed.
  • We depend on third parties to manufacture Triferic. If these organizations are unable or unwilling to manufacture our drug products, or if these organizations fail to comply with FDA or other applicable regulations or otherwise fail to meet our requirements, our business will be harmed.
  • We rely on third party suppliers for raw materials and packaging components of our drug products. We may not be able to obtain the raw materials and proper components we need, or the cost of the materials or components may be higher than expected, any of which could impair our production or commercialization of drug products and have a material adverse effect on our business, results of operations and financial position.
  • We may not be successful in obtaining foreign regulatory approvals or in arranging out-licensing partners capable of obtaining the approvals needed to effectively commercialize Triferic (dialysate), Triferic AVNU or any other drug product candidates outside of the United States. Even if we, or our partners, are successful in obtaining the required regulatory approvals, we may not be effective at marketing our drug products in certain markets or at all.
  • If Triferic (dialysate), Triferic AVNU or any other drug product candidates are approved and marketed outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.
  • We may not be successful in expanding our drug product portfolio or in our business development efforts related to in-licensing, acquisitions or other business collaborations. Even if we are able to enter into business development arrangements, they could have a negative impact on our business and our profitability.
  • Our drug business depends on government funding of health care, and changes could impact our ability to be paid in full for our drug products, increase prices or cause consolidation in the dialysis provider market.
  • We have in-licensed rights to certain patents that cover our products. If we fail to remain in compliance with these license agreements, we could forfeit the rights to these patents, which could negatively impact our ability to commercialize our products.
  • New classes of drugs, such as HIF-PHIs, may limit the need for iron to be administered to ESKD patients.
  • Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results.
  • If we experience delays in clinical testing, our commercial prospects will be adversely affected, our costs may increase and our business may be harmed.
  • If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • FPC may cause undesirable side effects or have other properties in the new disease states we are investigating that could delay or prevent their regulatory approval or limit the commercial profile of an approved label.
  • Lack of efficacy, adverse events, administration challenges or limitations, or undesirable side effects may emerge in clinical trials conducted by third parties developing treatment candidates in the disease states that we are investigating, which could adversely affect our stock price, our ability to attract additional capital and our development program.
  • Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if we are able to obtain regulatory approvals for our future product candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.
  • Even if our FPC pipeline product candidates receive regulatory approval, it may still face future development and regulatory difficulties.
  • We may be required to repay a portion of the upfront fees received from Baxter, which could materially and adversely affect our financial position and cash reserves.
  • A few customers account for a substantial portion of the end user sales of our concentrate products. The loss of any of these customers could have a material adverse effect on our business, results of operations, financial position and cash flows.
  • We face competition in the concentrate market and have a large competitor with substantial resources.
  • We may be affected materially and adversely by increases in raw material and transportation costs.
  • Our Loan Agreement with Innovatus contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation. The occurrence of any of these events could cause a significant adverse impact on our business, prospects and share price.
  • Our existing capital resources may not be adequate to finance our operating cash requirements for the length of time that we have estimated and additional capital that we may need to operate or expand our business may not be available.
  • Our business could be impacted as a result of actions by activist shareholders, including as a result of a potential proxy contest for the election of directors at our annual meeting.
  • Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.
  • We are and may become the target of additional securities and shareholder litigation, which is costly and time-consuming to defend.
  • Any adverse conclusions from our SEC investigation could result in fines, criminal penalties and an adverse effect on our business.
  • Unfavorable weather or global economic conditions could adversely affect our business, financial condition or results of operations.
  • Our drug and concentrate businesses are highly regulated, resulting in additional expense and risk of noncompliance that can materially and adversely affect our business, results of operations, financial position and cash flows.
  • We could be found to be infringing intellectual property rights of third parties, which could prevent us from selling products and could require us to pay significant damages and compel us to defend against litigation. We may be subject to claims that our employees or directors have wrongfully used or disclosed alleged trade secrets of their former employers.
  • Shares eligible for future sale may affect the market price of our common stock.
  • The market price for our common stock is volatile.
  • Our ability to use our net operating loss carryforwards to offset potential taxable income and related income taxes that would otherwise be due may be limited.
  • We do not anticipate paying dividends in the foreseeable future.
Management Discussion
  • During the year ended December 31, 2020, our net sales were $62.2 million compared to net sales of $61.3 million during the year ended December 31, 2019. Net sales of hemodialysis concentrates to dialysis providers and distributors in the United States and abroad were $61.1 million for the year ended December 31, 2020 compared to $60.8 million for the year ended December 31, 2019. The increase of $0.3 million was primarily due to increase in sales to our domestic customers offset by a decrease in international sales. Net sales of Triferic (dialysate) were approximately $1.1 million for the year ended December 31, 2020 compared to $0.5 million for the year ended December 31, 2019. For each year ended December 31, 2020 and 2019, Triferic net sales included approximately $0.2 million of deferred revenue recognized under the Company’s license in the People’s Republic of China with Wanbang.
Content analysis
H.S. sophomore Avg
New words: accredited, accretion, adaptation, advice, Aid, altogether, ampule, apparent, artwork, ATM, atom, AVNU, belonging, biggest, biochemical, bleach, breath, bridge, broader, cap, cardiac, carryback, carve, caution, challenge, challenged, challenging, comfort, comorbidity, constraint, contact, counter, covenant, cycle, deal, Dear, decree, dehydration, descale, detain, deterrent, dialogue, diet, disbanded, discover, discovered, disinfection, display, disseminated, driven, drop, dysfunction, endorsement, energy, enlist, ESKD, evidentiary, evolution, explicitly, fashion, faster, fatigue, flooding, footprint, foreclose, formulary, FPC, freezing, frequency, fullest, furlough, geological, gluconate, gram, halt, hard, hearing, heart, heighten, heightened, hemodiafiltration, hesitant, Hgb, hospital, hospitalization, hospitalized, HPN, hypersensitivity, IDA, imposition, inadequacy, incompatibility, inconsistent, inconvenient, increasingly, incremental, inflamed, infrequently, inhibit, inhibitor, Inline, inpatient, irregular, iteration, Jeil, justify, Korea, Korean, Lastly, LATAM, LDO, lender, lifestyle, live, loading, logistical, logistically, loop, mandate, MDO, mechanistic, Medicine, mental, merging, mobilization, moot, movement, multitude, muscle, myocardial, NaN, navigate, nhia, objective, occasionally, older, onset, open, opioid, overcome, overlooked, oxidative, pain, pandemic, panel, path, pause, payer, penalty, peptide, perception, persist, persuade, physical, pledged, poor, port, portrayal, postponed, PPE, preliminarily, prioritizing, problem, proven, Radie, rapidly, recession, refinancing, regain, repayment, restructured, resume, resuming, revoke, revoked, Road, salary, salt, screened, SDO, sector, seize, session, shorten, sick, situation, skeletal, Skibsted, slowdown, smooth, solid, sooner, sponsorship, stay, sterile, stratify, strict, sublease, sucrose, suitable, surge, synergistic, talent, tank, tied, tightly, timeline, TM, topline, toxicity, toxicology, traditional, tranche, tremendously, unaccreted, unamortized, undertreated, underwritten, unimpeded, University, unresponsive, uptake, uptick, uremia, verification, visit, visual, Wainwright, weekly, workplace, worsen
Removed: abbreviated, accurately, article, ASU, attempt, attestation, attorney, Benjamin, Calcitriol, complied, confidence, conversion, COSO, Curfman, David, declaratory, delaying, detection, Dismissal, dismissed, dismissing, drum, earliest, excessive, existence, expensing, FASB, harbor, highest, House, hypocalcemia, implementing, introduced, invested, jointly, limiting, literature, Matthew, memorialize, nominate, nominating, notably, passage, patented, percent, pertain, PPACA, predominant, prejudice, prepay, prevail, prevention, priced, pursuing, RBI, recognizing, reducing, remained, repeal, Richmond, rigid, rotation, Senate, size, spending, standstill, stipulated, suit, targeting, title, Topic, treasury, Trump, unqualified, usage, vitamin, withdrew, Wolin